Vita 34 AG
XETRA:V3V

Watchlist Manager
Vita 34 AG Logo
Vita 34 AG
XETRA:V3V
Watchlist
Price: 4.16 EUR -0.95% Market Closed
Market Cap: 72.5m EUR
Have any thoughts about
Vita 34 AG?
Write Note

Intrinsic Value

The intrinsic value of one V3V stock under the Base Case scenario is 3.6 EUR. Compared to the current market price of 4.16 EUR, Vita 34 AG is Overvalued by 13%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

V3V Intrinsic Value
3.6 EUR
Overvaluation 13%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Vita 34 AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for V3V cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about V3V?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Vita 34 AG

Provide an overview of the primary business activities
of Vita 34 AG.

What unique competitive advantages
does Vita 34 AG hold over its rivals?

What risks and challenges
does Vita 34 AG face in the near future?

Has there been any significant insider trading activity
in Vita 34 AG recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Vita 34 AG.

Provide P/S
for Vita 34 AG.

Provide P/E
for Vita 34 AG.

Provide P/OCF
for Vita 34 AG.

Provide P/FCFE
for Vita 34 AG.

Provide P/B
for Vita 34 AG.

Provide EV/S
for Vita 34 AG.

Provide EV/GP
for Vita 34 AG.

Provide EV/EBITDA
for Vita 34 AG.

Provide EV/EBIT
for Vita 34 AG.

Provide EV/OCF
for Vita 34 AG.

Provide EV/FCFF
for Vita 34 AG.

Provide EV/IC
for Vita 34 AG.

Show me price targets
for Vita 34 AG made by professional analysts.

What are the Revenue projections
for Vita 34 AG?

How accurate were the past Revenue estimates
for Vita 34 AG?

What are the Net Income projections
for Vita 34 AG?

How accurate were the past Net Income estimates
for Vita 34 AG?

What are the EPS projections
for Vita 34 AG?

How accurate were the past EPS estimates
for Vita 34 AG?

What are the EBIT projections
for Vita 34 AG?

How accurate were the past EBIT estimates
for Vita 34 AG?

Compare the revenue forecasts
for Vita 34 AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Vita 34 AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Vita 34 AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Vita 34 AG compared to its peers.

Compare the P/E ratios
of Vita 34 AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Vita 34 AG with its peers.

Analyze the financial leverage
of Vita 34 AG compared to its main competitors.

Show all profitability ratios
for Vita 34 AG.

Provide ROE
for Vita 34 AG.

Provide ROA
for Vita 34 AG.

Provide ROIC
for Vita 34 AG.

Provide ROCE
for Vita 34 AG.

Provide Gross Margin
for Vita 34 AG.

Provide Operating Margin
for Vita 34 AG.

Provide Net Margin
for Vita 34 AG.

Provide FCF Margin
for Vita 34 AG.

Show all solvency ratios
for Vita 34 AG.

Provide D/E Ratio
for Vita 34 AG.

Provide D/A Ratio
for Vita 34 AG.

Provide Interest Coverage Ratio
for Vita 34 AG.

Provide Altman Z-Score Ratio
for Vita 34 AG.

Provide Quick Ratio
for Vita 34 AG.

Provide Current Ratio
for Vita 34 AG.

Provide Cash Ratio
for Vita 34 AG.

What is the historical Revenue growth
over the last 5 years for Vita 34 AG?

What is the historical Net Income growth
over the last 5 years for Vita 34 AG?

What is the current Free Cash Flow
of Vita 34 AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Vita 34 AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Vita 34 AG

Current Assets 37.9m
Cash & Short-Term Investments 16.1m
Receivables 16.3m
Other Current Assets 5.5m
Non-Current Assets 119.7m
Long-Term Investments 1.5m
PP&E 37m
Intangibles 55.4m
Other Non-Current Assets 25.7m
Current Liabilities 53.1m
Accounts Payable 7.2m
Other Current Liabilities 45.9m
Non-Current Liabilities 81.5m
Long-Term Debt 12.7m
Other Non-Current Liabilities 68.7m
Efficiency

Earnings Waterfall
Vita 34 AG

Revenue
78.8m EUR
Cost of Revenue
-48.9m EUR
Gross Profit
29.9m EUR
Operating Expenses
-32m EUR
Operating Income
-2.1m EUR
Other Expenses
2m EUR
Net Income
-127k EUR

Free Cash Flow Analysis
Vita 34 AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

V3V Profitability Score
Profitability Due Diligence

Vita 34 AG's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
38/100
Profitability
Score

Vita 34 AG's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

V3V Solvency Score
Solvency Due Diligence

Vita 34 AG's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Low D/E
Negative Net Debt
Long-Term Solvency
55/100
Solvency
Score

Vita 34 AG's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

V3V Price Targets Summary
Vita 34 AG

Wall Street analysts forecast V3V stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for V3V is 6.43 EUR with a low forecast of 6.36 EUR and a high forecast of 6.62 EUR.

Lowest
Price Target
6.36 EUR
53% Upside
Average
Price Target
6.43 EUR
54% Upside
Highest
Price Target
6.62 EUR
59% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for V3V?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for V3V is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

V3V Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Vita 34 AG Logo
Vita 34 AG

Country

Germany

Industry

Health Care

Market Cap

72.5m EUR

Dividend Yield

0%

Description

Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen and currently employs 124 full-time employees. The company went IPO on 2007-03-27. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The firm acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.

Contact

SACHSEN
Leipzig
Deutscher Platz 5a
+49341487920.0
www.vita34.de

IPO

2007-03-27

Employees

124

Officers

Chairman of the Management Board & CEO
Mr. Jakub Julian Baran
Vice President of the Management Board & Chief Commercial Officer
Mr. Tomasz Franciszek Baran
Chief Financial Officer
Thomas Pfaadt
Managing Director of Secuvita
Santiago Luengo

See Also

Discover More
What is the Intrinsic Value of one V3V stock?

The intrinsic value of one V3V stock under the Base Case scenario is 3.6 EUR.

Is V3V stock undervalued or overvalued?

Compared to the current market price of 4.16 EUR, Vita 34 AG is Overvalued by 13%.

Back to Top